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ABSTRACT
Despite the rapid development of CRISPR/Cas9-
mediated gene editing technology, the gene editing
potential of CRISPR/Cas9 is hampered by low effi-
ciency, especially for clinical applications. One of the
major challenges is that chromatin compaction in-
evitably limits the Cas9 protein access to the target
DNA. However, chromatin compaction is precisely
regulated by histone acetylation and deacetylation.
To overcome these challenges, we have comprehen-
sively assessed the impacts of histone modifiers
such as HDAC (1–9) inhibitors and HAT (p300/CBP,
Tip60 and MOZ) inhibitors, on CRISPR/Cas9 medi-
ated gene editing efficiency. Our findings demon-
strate that attenuation of HDAC1, HDAC2 activity, but
not other HDACs, enhances CRISPR/Cas9-mediated
gene knockout frequencies by NHEJ as well as gene
knock-in by HDR. Conversely, inhibition of HDAC3 de-
creases gene editing frequencies. Furthermore, our
study showed that attenuation of HDAC1, HDAC2 ac-
tivity leads to an open chromatin state, facilitates
Cas9 access and binding to the targeted DNA and in-
creases the gene editing frequencies. This approach
can be applied to other nucleases, such as ZFN and
TALEN.
INTRODUCTION
CRISPR/Cas9 (clustered regularly interspaced short palin-
dromic repeats/CRISPR-associated protein 9) is derived
from the bacterial immune system where it disrupts foreign
genetic elements invaded from plasmids and phages, which
are eventually naked DNA. Nowadays, it is widely used
in genome editing for eukaryotes, including humans (1–
5). However, the eukaryotic chromosomes are more com-
plex than their prokaryotic counterparts. In eukaryotes,
DNA is packed into chromosomes in the cell nucleus in a
highly compact and organized manner named chromatin.
The chromatin is made up of repeating units called nu-
cleosomes. The nucleosome consists of 147 bp wrapped
around histone protein octamers H2A, H2B, H3 and H4
(6). Thus, the gene editing process of CRISPR/Cas9 in eu-
karyotes is very different as compared to the prokaryotic
process.
CRISPR/Cas9 system is revolutionizing the field of bio-
chemical research, but a higher efficiency is anticipated
for clinical practice. The efficiency of genome editing by
CRISPR/Cas9 varies from 2% to ∼25% depending on
the cell type (7), which is not yet up to the requirements
for clinical use, such as cancer gene therapy (8). Most
approaches for optimizing CRISPR based techniques are
mainly focused on optimizing the structure of gRNAs
(9–11), creating mutant Cas9 (12) and finding new ver-
sions of CRISPR/Cas system from prokaryotes (13–16),
etc. Although these approaches are essential, the under-
lying genomic context, particularly the chromatin state of
the target locus, significantly influences the cleavage effi-
ciency (17,18). Recent studies showed that the targeting ef-
ficiency of CRISPR/Cas9 varied widely in different tar-
get loci of the chromosome (18,19). The euchromatic tar-
get sites show higher frequencies of DSB (double-strand
break) introduced by TALENs and CRISPR/Cas9 as com-
pared to those of the heterochromatic sites. Notably, a re-
cent study showed that the spontaneous breathing of nucle-
osomalDNAand chromatin remodelling facilitates Cas9 to
effectively act on chromatin (20). Thus, the chromatin con-
formations can significantly impact gene editing efficiency
of nucleases.
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Undoubtedly, there is a considerable number of target
sites inevitably located in heterochromatin, which has a
strong effect on the accessibility of DNA to Cas9 (21). Fur-
thermore, albeit many genes are located in a relatively eu-
chromatic position, the gene editing efficiency may also be
enhanced through maintaining the open state of those eu-
chromatic regions. But the approaches on how to manipu-
late the chromatin state and efficiently target those genes in
heterochromatin sites are lacking. The open or closed state
of chromatin structure is mainly controlled by the balance
of histone acetylation and deacetylation which is strictly
regulated by two groups of enzymes called HAT (histone
acetyltransferase) andHDAC (histone deacetylase) (22,23).
Briefly, histone acetylation leads to a loose or uncoiling
of the chromatin structure (euchromatin). Conversely, hi-
stone deacetylation leads to a condensed or closed chro-
matin structure (heterochromatin). The euchromatin gives
the transcriptional machinery access to the transcription-
ally active DNA (23), which also provides a great oppor-
tunity for CRISPR/Cas9 attacking and cutting the DNA,
particularly for the targets located in condensed heterochro-
matin regions. More importantly, the chromatin state regu-
lated by HAT and HDAC may also have the potential to
influence the gene knock-in mediated by HDR (homolo-
gous directed repair), which has extremely low efficiency
and needs to be improved (7,24). In addition, previous stud-
ies showed that the dCas9 (dead Cas9) fused to core p300 or
HDAC3 robustly influences epigenome editing (25,26), but
the effects of these HATs or HDACs on genome editing of
CRISPR/Cas9 have yet to be characterized.
Given the development of histonemodifiers such asHAT,
HDAC inhibitors and other biotechnology approaches (27),
it is possible and rational to explore whether the gene edit-
ing efficiency can be improved by altering the chromatin
state through modulation of the HDAC and HAT activ-
ity. We hypothesized that the regulation of chromatin com-
paction by inhibiting HAT and/or HDAC activity can
modulate CRISPR/Cas9 based gene editing. Our findings
show that inhibition of HDAC1,HDAC2, rather than other
HDACs, can enhance both gene knockout and gene knock-
in. We also show that inhibition of HDAC3 could decrease
the efficiency of CRISPR/Cas9mediated gene editing. Fur-
thermore, we provide a practical and clinically applicable
approach for precise control of CRISPR/Cas9 mediated




HEK293T, HeLa and HT29 cells were purchased from
American Type Culture Collection (ATCC, Wesel, Ger-
many). H27 (28), HEK.EGFPTetO.KRAB and HT29- EGFP
is a single cell-derived clone from HeLa, HEK293 and
HT29 for constitutively expressing EGFP, which have been
described elsewhere (18,29,30). All cells were cultured in
DMEM medium (Gibco® by Life Technologies) supple-
mented with 10% fetal bovine serum (FBS; Invitrogen,
Breda, The Netherlands) and 1% Penicillin/Streptomycin
(Gibco® by Life Technologies) at 37◦C with 5% CO2, un-
less otherwise indicated.
Chemical reagents
The HDAC and HAT inhibitors Entinostat, RGFP966,
C646, MG149, TMP195, PC134051 were purchased from
Selleckchem. The purity of these inhibitors was assessed by
Selleckchem (>99%). The Entinostat analogues have been
described elsewhere (31).
Cell viability detection
AnMTS assay was performed to determine the dose of the
HDACandHAT inhibitors that can be administrated to the
cells without affecting cell viability. Cells (3 × 103 per well)
were cultured overnight and incubated with corresponding
compounds in 96-well plates for 24 h. The next day, cells
were incubated at 37◦C with MTS for 90 min following the
instruction of CellTiter 96 AQueous One Solution Reagent
(Promega, Madison, USA). The absorbance was measured
at the wavelength of 490 nm by a Synergy H1 plate reader
(BioTek, Winooski, USA). Experiments were performed in
triplicate and repeated at least three times.
Recombinant plasmids
The construction of recombinant AdV (Adenovirus) shut-
tle plasmids has been detailed elsewhere (32). Briefly,
the recombinant plasmids contain PGK gene promoter
(phosphoglycerate kinase 1) and the SV40 (simian virus
40) polyadenylation signal. The pAdSh.PGK.Cas9 has a
PGK and SV40 element for controlling the hCas9 ex-
pression. The Cas9 ORF was isolated from plasmid Ad-
dgene #41815 (7). The gRNA expression units (gRNA-
GFP) based on the U6 RNA Pol III promoter were re-
trieved from plasmids Addgene #41820 (7). The constructs
above were inserted into the MCS of pAdSh.MCS.SV40,
resulting in the construct pAdSh.U6.gRNAGFP. The E1-
and E2A-deleted fiber-modified AdV molecular clones
pAdV2P.Cas9.F50 and pAdV2U6.gRNAGFP.F50 were as-
sembled in BJ5183pAdEasy-2.50 Escherichia coli via homolo-
gous recombination after transformation withMssI-treated
AdV shuttle plasmids (33).
For gene knock-in (EGFP-EBFP converting) experi-
ments, the recombinant DNA has been detailed elsewhere
(29). Briefly, the gRNA expression plasmid AX03 pgEGFP
and the hCas9 nuclease plasmid (Addgene plasmid 41815)
were used for generating DSBs at the EGFP sequence. The
AX63 pTHG was used as a donor template for converting
EGFP into EBFP via HDR. The AM51 pgNT was served
as a negative control.
Plasmid transfection
The plasmids transient transfection using PEI
(polyethyleneimine; Polysciences) has been detailed
elsewhere (18).
pAdV2P.Cas9.F50 and pAdV2U6.gRNAGFP.F50 viral vec-
tor production, purification and titration
The production of viral vectors AdV-Cas9 (adenovirus
contains Cas9 gene) and AdV-gRNA (Adenovirus con-
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pAdV2P.Cas9.F50 and pAdV2U6.gRNAGFP, respec-
tively, which have been described elsewhere (32–34). Briefly,
AdV particles were initiated by transfecting PER.E2A
cells using PEI solution and PacI-linearized plasmids
pAdV2P.Cas9.F50 and pAdV2U6.gRNAGFP.F50. After
overnight incubation at 39◦C, the culture media was
replaced and cells were transferred to 34◦C. The cells
were harvested and following by three cycles of freezing
and thawing in liquid nitrogen and in a 37◦C water bath.
Rescued AdVs presented in supernatants and amplified
through propagation on PER.E2A cells newly seeded
in a T75 flask. Large scale AdV produced in 16 T175
cell cultures flasks (Greiner Bio-One), following by CsCl
gradient centrifugation method for purification. The titers
of purified AdV were determined by TCID50 assay which
has been detailed (32).
AdTL Viral vector production and purification
AdTL (Adenoviral vector) is a both E1- and E3-deleted re-
combinant serotype 5 adenovirus which contains a GFP
(green fluorescent protein) and luciferase expression cas-
sette (35). The HEK293 cells were seeded in 10 T175 flasks
and transduced with AdTL in a dosage of 10 transduction
units (TU)/cell to produce a large batch of viruses. When
CPE (cytopathic effect) of 100% was reached, the cells were
harvested and centrifuged at 1000 rpm for 5 min. The pellet
was subjected to three cycles of freezing and thawing using
dry ice and a 37◦C water bath, respectively. Subsequently,
the suspension was centrifuged again at 4000 rpm for 10
min. The supernatant was purified using a Q-sepharose-XL
column for chromatography of adenovirus as described pre-
viously (36). Separations were carried out using a flow rate
of 2 ml/min. The column was equilibrated using 25 ml ap-
plication buffer (50 mM Tris–HCl pH 8,0 1.0 mMMgCl2).
Thereafter, the AdTL virus, dissolved in 5 ml application
buffer, was loaded on the column. The column was washed
with 25 ml application buffer followed by 25 ml wash buffer
(containing 0.3 M NaCl). The virus was eluted from the
column using 5 ml elution buffer (containing 1 M NaCl).
The column was cleaned using 10 ml 0.1 M NaOH fol-
lowed by 25 ml demi H2O. An OD260 measurement was
performed using the NanoDrop 1000 Spectrophotometer
(ThermoFisher Scientific, USA) to determine the number
of virus particles. In addition, a limiting dilution assay with
AdTL dilutions was performed to determine the TCID50.
Furthermore, purification by the Q sepharose XL column
was checked by loading non-purified and purified AdTL
virus, mixed with SDS loading buffer (4×) on a 12,5% SDS-
PAGE gel, which was run for 2 h at 160 V. Subsequently, the
gel was stained with Instant Blue for 30 min to make pro-
teins visible. Furthermore, the purified virus was placed in a
dialysis frame (Pierce) and dialyzed in dialysis buffer (10%
glycerol, 10 mM HEPES, 1 mM MgCl, pH 7.4) to remove
the elution buffer, after which a final limiting dilution assay
was performed.
Transduction experiments
Cells were co-transduced with AdV-Cas9 and AdV-
gRNA to measure whether HDAC/HAT inhibitors af-
fect the quantity of EGFP gene knockout induced by
CRISPR/Cas9. Cells were seeded with a density of 200 000
cells/well in a six-well plate. After 24 h, the medium was
replaced by medium (5% FBS) containing HDAC/HAT
inhibitors with indicated dose. After 24 h, the cells were
co-transduced with AdV-Cas9 and AdV-gRNA in a quan-
tity of 30 TU/well. All co-transductions were performed in
a 1:1 ratio. Cells were subcultured for 12 days to remove
EGFP protein from cells with disrupted EGFPORFs. Sub-
sequently, fluorescencemicroscopy, flow cytometry, western
blot and the T7E1 assay were performed to assess which
percentage of EGFP genes in cells had been cleaved by
CRISPR/Cas9.
Furthermore, mock transducedH27 cells served as a con-
trol to determine the effect of the different compounds
on the endogenous EGFP gene expression. Twenty four
hours prior to treatment, H27 cells were seeded with a den-
sity of 200 000 cells/well. Subsequently, the cells were ex-
posed to a medium containing the same concentrations of
HDAC/HAT inhibitors as the knockout assay. After three
days, flow cytometry was performed to determine the inten-
sity of EGFP expression.
HeLa and HT29 (without EGFP) cells were transduced
with theAdTL virus, which encodes forGFP and luciferase,
to determine the effect of the HDAC/HAT inhibitors on
transgene expression levels. HeLa cells were seeded at a
density of 400 000 cells/well in a six-well plate. After 24
h, the medium was replaced by a medium containing indi-
cated doses of HDAC/HAT inhibitors. After 24 h incuba-
tion with the compounds, AdTL was added at a dosage of
30 TU/cell. Mock- transduced cells served as control. Af-
ter three days, flow cytometry was performed on the AdTL
transduced cells. When a difference in transgene expression
was detected, an additional experiment was performed to
clarify whether the effect was due to a difference in viral
transduction or transcription of the transgene. This was de-
termined by administration of the compound 24 h prior to
AdTL transduction or immediately after AdTL transduc-
tion.
Gene-editing (NHEJ and HDR) based on EGFP -to- EGFP
fluorochrome conversion using plasmid donor
HEK.EGFPTetO.KRAB cells were seeded at 2 × 105 per
well of six-well plates overnight. Before DNA transfection,
cells were treated with indicated compounds for 48 h. The
DNA transfection was performed by adding 1 mg/ml PEI
with different plasmids including Cas9, pTHG. Donor and
gRNA-EGFP-containing RGNs which have been detailed
elsewhere (29). The different transfection complex was re-
placed by regular culturemedium in the presence or absence
ofDox (Doxycycline, Tocris Bioscience). The cells were sub-
cultured circa every 3 days for up to 11 days. The frequen-
cies of EGFP-negative and EBFP-positive cells cultured in
medium with Dox or without Dox were determined by flow
cytometry.
Cell cycle assay
Cell cycle experiment was using PI (Propidium Iodide,
Sigma P4864-10ML) combined with BrdU (Bromod-
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seeded at 20 000 cells/well of six-well plates. BrdU was
added and incubated 30 min at 37◦C after 24 h HDAC
inhibitors treatment with different concentrations. Next,
cells were harvested and fixed using ice-cold 70% ethanol
for 30 min on ice. The genomic DNA of cells were dena-
tured by adding 2 M HCl containing 0.5% Triton X-100
and incubated for additional 30 min at room temperature.
Next, BrdU-labeled cells were neutralized by adding 0.1 M
Na2B4O7·10 H2O (pH 8.5). Diluted anti-BrdU antibody
(APC anti-BrdU Antibody, Biolegend) was added and in-
cubated with cells at 4◦C overnight according to manufac-
turer’s protocol. Antibody treated cells were resuspended in
1× PBS (Phosphate Buffered Saline) contains PI (1 mg/ml)
andRNase (10mg/ml) next day. The different phases of cell
cycle were determined by flow cytometry.
HDAC1, 2 and 3 knockdown by siRNAs
For HDAC knockdown, H27 and HT29 cells were trans-
fected using Lipofectamine 2000 (Invitrogen, Carlsbad,
USA). Cells were seeded at 2 × 105 per well of six-well
plates overnight. On the next day, cells were transfected
with siRNAs (100 nM/well) against HDAC1 (MISSION,
esiRNA HDAC1), HDAC2 (MISSION, esiRNA HDAC2)
and HDAC3 (M-003496-02-0005, siGENOME). siRNAs
for HDAC1 and HDAC2 were purchased from Millipore
Sigma (Burlington, MA, USA). siRNAs for HDAC3 were
purchased from GE Healthcare Dharmacon (Lafayette,
CO, USA), or control siRNAs (Burlington, MA, USA). At
least three gene-specific siRNAs were used for each gene si-
lencing. After 3 days post-transfection, cells were lysed us-
ing RIPA buffer.
RNA extraction and qRT-PCR (quantitative reverse tran-
scriptase PCR)
Cells were washedwith PBS and harvested by trypsin. RNA
was extracted by the Maxwell LEV simply RNA Cells Kit
(Promega, Madison, USA). RNA concentrations were de-
termined by NanoDrop 1000 Spectrophotometer (Thermo
Fisher Scientific, Waltham, USA). cDNA was synthesized
using 200 ng total RNA by the Reverse Transcription kit
(Promega, Madison, USA) according to the instruction.
Primers are listed in Supplementary Table S1. Primers used
for Cas9 and gRNA expression have been described (37).
Data analysis was processed by SDS v.2.3 software (Applied
Biosystems, Foster City, USA).
Fluorescence microscopy
Targeted EGFP knockout and AdTL transgene expression
were monitored by fluorescence microscopy using a Zeiss
Axiovert 25 CFL inverted light microscope (Carl Zeiss AG,
Germany) with a 450–490 nm excitation and 515 nm emis-
sion filter set.
Flow cytometric analysis
Cells were harvested and washed twice with standard FACS
buffer (PBS plus 1% FBS). The proportion of EGFP posi-
tive cells were quantified using FACS Calibur flow cytome-
ter (BD, Franklin Lakes, USA). For EGFP and EBFP con-
verting mediated gene knock-in study, the BD FACSVerse
cytometer (BD, Franklin Lakes, USA) was used. All the
experiments were performed at the Central Flow cytome-
tryUnit (UniversityMedical CenterGroningen). Datawere
analysed by FlowJo 7.2.2 software (Tree Star).
Immunoblotting
Cells were washed with PBS and harvested by trypsiniza-
tion. Cells were lysed using RIPA buffer with PIC (Pro-
tease Inhibitor Cocktail; Thermo Fisher Scientific, USA).
Protein concentrations were determined by a Pierce BCA
Protein Assay Kit (Thermo Fisher Scientific, USA). Sam-
ples were separated by pre-cast SDS-PAGE (Bio-Rad, Her-
cules, USA) and transferred using a PVDF membrane
(polyvinylidene difluoride). The PVDF membrane was
blocked with 5% skimmed milk in PBST (0.1% Tween-20)
at room temperature for 1 h and incubated at 4◦C overnight
with primary antibodies. Anti-rabbit or anti-mouse HRP
conjugated antibodies were used to detect protein by chemi-
luminescence using ECL (Perkin Elmer, Western Lightning
Plus ECL). Images were visualized by GeneSnap image
analysis software (SynGene, Frederick, USA) and quan-
tified with ImageJ software (National Institute of Health,
USA). The following antibodies from Cell Signalling were
used for immunoblotting, Cas9 (#14697), HDAC1 (#2062),
HDAC2 (#5113) and HDAC3 (#2632). The dilution of
primary antibodies was 1:1000 (v/v). The secondary an-
tibodies rabbit anti-mouse (#P0260) and goat anti-rabbit
(#P0448) HRP were purchased from Dako Denmark. The
dilution of secondary antibodies was 1:2000 (v/v). The di-
lution of fluorescent secondary antibody (#92632211 and
#92668070) was 1:10000 (v/v).
Chromatin immunoprecipitation (ChIP) and qPCR
Chromatin immunoprecipitation (ChIP) and qPCR were
performed to detect the alterations of chromatin state and
the binding of Cas9 to targeted DNA in the presence or in
the absence of HDAC inhibitors. The cells were cultured in
the presence or absence of inhibitors at an indicated dose
for 3 days, after which cell fixation was applied according
to the protocol as described before (18). Briefly, 2 ml of
11% formaldehyde solution were added to the cell culture
medium. The culture flasks were agitated for 15min at room
temperature. Next, 1.1 ml of 2.5 M glycine was used to stop
the fixation process. After a 5 min incubation at room tem-
perature, cells were transferred to a 50 ml tube. The har-
vested cells were subjected to centrifugation at 1350 × g for
5 min at 4◦C for two cycles with PBS. Subsequently, the
nuclei were isolated using pre-chilled solution (0.1% NP-
40 in PBS) and collected by centrifuging at 10 000 rpm at
4◦C for 10 s. Next, to obtain DNA fragments, MNase (Mi-
crococcal Nuclease) was used according to the manufac-
turer’s instruction. The ChIP-qPCR assays were carried out
on 30 g of cross-linked chromatin according to the His-
tonePath™ (ActiveMotif) ChIP-qPCRprotocol. The ChIP-
validated antibodies H3 pan-acetyl (Active Motif, cat #
39139) and Cas9 antibody (mAb) (8C1-F10) were used for
theChIP.Next, qPCRamplifications with primers targeting
different regions (i.e. EF1 promoter, 5′ and 3′ EGFP gene
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ORF primers were used. Additional primer pairs were used
for the quality control of the ChIP-qPCR assays. All of the
primer sequences have been detailed (18).
The qPCR amplifications were performed in an ABI
Prism 7900HT Sequence Detection System. The qPCR am-
plifications were performed in triplicate for each sample
with the following procedures: a 2-min incubation period
at 95◦C, followed by 40 cycles with at 95◦C for 15 s, at
58◦C for 20 s at 72◦C for 20 s. Next, the samples were in-
cubated at 95◦C, 55◦C for 1 min, respectively. The binding
events detecting every 1000 cells were calculated based on
input amounts of chromatin, final ChIP volumes, and the
primer efficiencies. Finally, the data were normalized ac-
cording to the algorithm developed by Active Motif, Inc.
(Carlsbad, CA, USA), which is available as an online tool
(https://www.activemotif.com).
MNAse-qPCR
MNAse-qPCR protocol was adapted from an earlier de-
scribed method (38). In brief, nuclei were isolated by re-
suspending a cell pellet in 1 ml of ice-cold PBS containing
0.1%NP-40 supplemented with 1× PIC (cOmplete™, Mini,
EDTA-free, Roche). The cell suspension was vortexed for
five seconds at max. speed followed by centrifugation for
5–10 s at 9000 × g. The supernatant was discarded and the
pellet was resuspended in 1ml ice-cold PBS containing 0.1%
NP-40 supplemented with 1× PIC to wash the nuclei. The
nuclei were spun down again for 5–10 s at 10 000 rpm and
the supernatant was again discarded. Next, the nuclei were
resuspended in 100 l MNAse buffer (50 mM Tris–HCl, 5
mM CaCl2, 100 g/ml BSA, pH 7.9) and warmed to 37◦C
in a water bath, followed by addition of 5 U (unit) MNAse
(NEB, diluted to 1 U/l in MNAse buffer). MNase diges-
tion was stopped after 5 min by adding EDTA to a final
concentration of 5 mM and cooling on ice. The suspension
was spun down for 5–10 s at 10 000 rpm and the supernatant
was transferred to a new tube (pellet contains nuclear de-
bris). Proteinase K was added to a final concentration of 1
mg/ml and incubated for 1 h at 50◦C.DNAwas size selected
and purified with Ampure beads according to the manu-
facture’s protocol (AMPure XP, A63881, Beckman Coul-
ter, USA). First 0.7× sample vol. of Ampure beads were
added and after a 5 min incubation at room temperature
the beads were discarded (to discard largeDNA fragments).
Next, 1.8× original sample vol. Ampure beads were added
and work-up was performed according to the product man-
ual. The DNA was eluted in 80 l water.
The qPCR amplifications were performed in an ABI
Prism 7900HT Sequence Detection System. The proto-
col was described as previously. Data were analyzed using
QuantStudio™ Real-Time PCR software (ThermoFisher
Scientific, USA).
T7E1 assay
To determine the genome targeting efficiency of
CRISPR/Cas9, T7E1 (T7 endonuclease 1 assay) was
performed. H27 cells were harvested and genomic DNA
was isolated using Genomic DNA purification kit (Qia-
gen, Germany) following the manufacturer’s instructions.
The concentration of the isolated genomic DNA was
determined using The NanoDrop 1000 Spectrophotome-
ter (ThermoFisher Scientific, USA). Thereafter, a PCR
was performed using Taq polymerase (NEB, USA) with
primers 5′ GAGCTGGACGGCGACGTAAACG 3′ and 5′
CGCTTCTCGTTGGGGTCTTTGCT 3′ for amplification
(Sigma-Aldrich, Germany). The PCR amplification was as
follows: an initial denaturation 95◦C for 5 min, samples
were subjected to 35 cycles of denaturation at 95◦C for
30 se, annealing at 53◦C for 30 s and elongation at 72◦C
for 40 s. Amplified DNA products were mixed with 1.5 l
NEB Buffer 2 and 3.0 l nuclease-free water. An initial
denaturation was performed following a ramp rate −2◦C
/second from 95◦C and then −0.1◦C /second from 85◦C
to 25◦C. Subsequently, 1 l T7E1 enzyme (NEB, USA)
was added and incubated at 37◦C in a water bath for 15
min. Gel electrophoresis was performed for detecting DNA
fragments.
Sanger sequencing for detection of off-target effects
Sanger sequencing was performed by Eurofins Genomics’
DNA sequencing service according to the instruction. The
primers are listed in supplementary data.
Nextera XT DNA Library Prep for Next-Generation Se-
quencing
Input DNA was tagmented and amplified using Illumina’s
Nextera XT DNA Library Prep. Libraries were quanti-
fied with Thermo’s Qubit high-sensitivity DNA kit and run
on the Agilent high sensitivity D1000 ScreenTape system
for quality control. Sequencing was performed on NextSeq
500 (Illumina) using NextSeq 500 75-cycle High Output kit
v2.5.
Bioinformatic analysis
Reads were aligned using bowtie2 v2.2.4. against 710 bp
reference sequence. Indel realignment was performed us-
ing GATK version 3.8.0 on merged (all libraries analysed)
BAMfiles. Quantification of polymorphisms was done with
help of samtools mpileup command. A custom Perl script
(available upon request) was used to parse the output into
a summary table.
Statistical analysis
The data were presented asmean± SD (unless otherwise in-
dicated). Data were derived from at least three independent
experiments (unless otherwise indicated). Statistical analy-
sis was performed by GraphPad software v.5.0 (La Jolla,
CA, USA). Data were analyzed by a two-tailed unpaired
Student’s t-test (unless otherwise indicated). *P-values <
0.05; **P-values < 0.01; ***P-values < 0.001.
RESULTS
The landscape of HDAC/HAT inhibition on CRISPR/Cas9-
mediated gene knockout
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Figure 1. Screening HDAC inhibitors for improving CRISPR/Cas9 mediated gene editing. (A) Schematics of HDAC inhibitors screening procedures for
CRISPR/Cas9 mediated gene knockout. CRISPR/Cas9 specifically cuts the EGFP sequence in HeLa (H27) and HT29 cells resulting in EGFP signal
loss (28,30,32). Cells were pre-treated with different inhibitors and incubated with AdV-Cas9 and AdV-gRNA, subsequently subcultured for 12 days to
remove EGFP protein from cells with disrupted EGFPORFs. EGFPGene editing efficiency is measured by FACS. (B) The effect of different HAT/HDAC
inhibitors on CRISPR/Cas9 mediated gene knockout in H27 and HT29 with Panobinostat (0.1 M), Entinostat (5 M), RGFP966 (1 M), TMP195 (1
M), PCI34051 (1 M), Tubastatin A (1 M), C646 (1 M) and MG149 (1 M). The frequencies of gene knockout were quantified by flow cytometry.
(C) T7EI genotyping assays for detection of indels induced by CRISPR/Cas9 in H27 cell line and quantified by ImageJ. (D) Endogenous EGFP expression
determined by flow cytometry with the treatment of different HDAC/HAT inhibitors. Data in bar graphs are represented as mean± SD (n≥ 3), two-tailed
unpaired Student’s t-test: *P-values < 0.05; **P-values < 0.01; ***P-values < 0.001.
CRISPR/Cas9-mediated gene knockout, we tested a panel
of HDAC/HAT inhibitors (Table 1) with a CRISPR/Cas9-
mediated EGFP (enhanced green fluorescent protein)
knockout reporter system (32) (Figure 1A). H27 andHT29-
EGFP is a single cell-derived clone from HeLa and HT29
for constitutively expressing EGFP, which have been de-
scribed elsewhere (18,28–30).
To preclude the interference of drug toxicity, we per-
formed a cell viability assay with the treatment of
HDAC/HAT inhibitors in H27 and HT29 cells (Supple-
mentary Figure S1). At least 90% of cell viability compared
to the control group was considered as acceptable. Accord-
ing to the cell viability data (Supplementary Figure S1), the
dose of each inhibitor without affecting cell viability are
Panobinostat (0.1 M), Entinostat (5 M), RGFP966 (1
M), TMP195 (1 M), PCI34051 (1 M), Tubastatin A (1
M), C646 (1 M) and MG149 (1 M) (Supplementary
Figure S1A).
A co-transduction grid experiment was performed to as-
sess which dosage of virally delivered gRNA and Cas9 re-
sults in high genomic EGFP gene knockout levels with-
out reducing cell viability. We observed that a dosage of
30 TU/cell resulted in relatively high amounts of EGFP
gene knockout as well as no reduction of cell viability
(Supplementary Figure S2). Therefore, we transduced 1:1
mixtures of and gRNA and Cas9 viral particles at 30
TU/cell, respectively, to induce DSBs at EGFP sequences.
The EGFP gene editing frequencies were determined by
direct fluorescence microscopy and flow cytometry at 14
days post-transduction. Our results showed that Entinos-
tat (HDAC1/2/3 inhibitor) and Panobinostat (pan-HDAC-
inhibitor) significantly increased gene knockout frequen-
cies in both H27 and HT29 cells by 1.5–3.4-fold (Figure
1B). Of note, RGFP966 (HDAC3 inhibitor) slightly de-
creased gene knockout frequencies as well as other HDAC
inhibitors (HDAC4–9) (Figure 1B). Additionally, HAT in-
hibitors C646 (p300/CBP inhibitor) and MG149 (Tip60
and MOZ inhibitor) decreased the EGFP gene knock-
out frequencies (Figure 1B). The gene knockout frequen-
cies enhanced by Entinostat and Panobinostat were fur-
ther determined by T7E1 (T7 endonuclease I) assay (Fig-
ure 1C). As controls, we did not observe gene knockout
in the groups with a single treatment (gRNA only, Cas9
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Table 1. List of HDAC/HAT inhibitors used in this study
Name HDAC1 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 P300/CBP Tip60 and MOZ
Panobinostat + + + + + + + + + − −
Entinostat + + + − − − − − − − −
RGFP966 − − + − − − − − − − −
TMP195 − − − + + − + − + − −
Tubastatin A − − − − − + − − − − −
PCI34051 − − − − − − − + − − −
C646 − − − − − − − − − + −
MG149 − − − − − − − − − − +
ate CRISPR/Cas9 target efficiency more precisely, we have
performed next generation sequencing to measure the tar-
geting efficiency. We observed a significant increase of tar-
get efficiency using Entinostat and Panobinostat. Accord-
ing to the next generation sequencing data, Entinostat and
Panobinostat increase the gene editing frequency by 3.7-
fold and 10.5-fold, respectively (Supplementary Figure S3).
To assess the possibility of the impacts of HDAC in-
hibitors on endogenous EGFP expression in H27 and
HT29, we tested the EGFP expression level using flow cy-
tometry and there were no changes of endogenous EGFP
expression, indicating no affection on endogenous EGFP
expression upon these HAT/HDAC inhibitors treatments
(Figure 1D).
Panobinostat and Entinostat enhance CRISPR/Cas9-
mediated gene knockout in a dose-dependent manner.
Next, we asked whether the enhancement of gene knock-
out by Panobinostat and Entinostat is dose dependent. We
tested the indicated amounts of Panobinostat and Enti-
nostat (Figure 2). Our results showed a positive correla-
tion between the EGFP gene knockout frequencies and the
dose of Panobinostat and Entinostat (Figure 2). These re-
sults clearly indicate that Panobinostat and Entinostat en-
hance CRISPR/Cas9-mediated gene knockout in a dose-
dependent manner.
Downregulation ofHDAC1 orHDAC2 increases gene knock-
out efficiency
Both Panobinostat (a pan-HDAC inhibitor) and Entino-
stat (an HDAC1/2/3 selective inhibitor) enhanced gene
knockout, but RGFP966 (an HDAC3 selective inhibitor)
decreased gene knockout. Moreover, we did not observe
the enhancement of gene knockout by other HDAC selec-
tive inhibitors. Therefore, we speculate that HDAC1/2/3
may play an important role in the gene editing process
of CRISPR/Cas9. To precisely distinguish the role of the
three HDACs in gene editing processes, we used siRNAs
to specifically knockdown HDAC1, HDAC2 or HDAC3 to
explore whether gene knockout efficiency can be enhanced
or decreased (Figure 3A). In agreement with the inhibitors
results above, we showed that knockdown of HDAC1 or
HDAC2 results in a significant increase by 16–28% and 22–
26% (P < 0.01) of EGFP gene knockout, respectively (Fig-
ure 3B). Moreover, our results showed that downregulation
of HDAC3 decreased the EGFP gene knockout efficiency
by 21% and 39% (P < 0.001) in H27 and HT29 cell lines,
respectively (Figure 3B). Thus, downregulation of HDAC1
or HDAC2 increases CRISPR/Cas9-mediated gene knock-
out, but downregulation of HDAC3 decreases it.
Effect of Panobinostat and Entinostat on viral transduction,
transgene transcription and cell cycle
Although we hypothesized that HDAC inhibitors may in-
crease the CRISPR/Cas9 mediated gene editing by increas-
ing the accessibility of the target loci, viral transduction
and transgene transcription might also influence the gene
knockout, particularly by affecting Cas9 protein expression
levels. Therefore, additional experiments were performed to
determine the influence of Panobinostat and Entinostat on
viral transduction and transgene expression.
To explore the impacts of Panobinostat and Entinos-
tat on adenovirus transduction and transgene expression,
we first tested with an EGFP reporter AdTL (Adenovi-
ral vector). Since H27 and EGFP-HT29 cells have en-
dogenous EGFP expression which may affect the measure-
ment, the original HeLa and HT29 cells without EGFP ex-
pression were employed. HeLa and HT29 wild-type cells
were treated with Entinostat and Panobinostat, respec-
tively, prior and post to AdTL infection to determine
adenovirus transduction and transgene expression. Subse-
quently, the effect of these HAT/HDAC inhibitors on the
expression of GFP was evaluated by flow cytometry. The
results showed that the expression of exogenous GFP by
AdTL increased dramatically upon Panobinostat treatment
in both pre- and post-treatment (Figure 4A). In contrast,
in the cells treated with Entinostat there was no significant
change (Figure 4A). These results indicate that Entinostat
does not affect adenovirus transduction and transgene ex-
pression.
To directly determine the effects of Panobinostat and
Entinostat on Cas9 expression, H27 and HT29 cells
were treated with Entinostat and Panobinostat, prior to
AdV-Cas9 infection. Subsequently, the effects of these
HAT/HDAC inhibitors on RNA levels of Cas9 and gRNA
were measured by qPCR and Cas9 protein levels were de-
termined by Western blot. We observed that Panobinos-
tat significantly increased RNA levels of Cas9 as well as
protein expression in HT29 cells, but Entinostat did not
show a significant increase of Cas9 expression in both RNA
and protein levels (Figure 4B and C). Interestingly, we ob-
served Entinostat decreases gRNA expression levels in both
cell lines. Panobinostat increases gRNA expression in H27,
but decreases in HT29 (Figure 4B). These data indicated
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Figure 2. Dose dependent effects of Entinostat and Panobinostat on CRISPR/Cas9 mediated gene knockout. The dosage of Entinostat are 0, 0.5, 1 and
5 M and Panobinostat are 0, 25, 75, 100 nM. Dose-dependent response to Entinostat and Panobinostat was assessed by flow cytometry. Data were
derived from three independent experiments. The quantification bar graph (right) generated according to flow cytometry data (left). Data in bar graphs
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Figure 3. Assessment of gene knockout frequencies by knockdown of HDAC1, HDAC2 and HDAC3. (A) HDAC1, HDAC2 and HDAC3 mRNA and
protein levels were determined by RT-qPCR and western blot after transfection with scrambled siRNAs or HDAC1, HDAC2 or HDAC3 siRNAs. (B)
Changes of EGFP knockout mediated by CRISPR/Cas9 upon knockdown of HDAC1, HDAC2 or HDAC3. Data in bar graphs are represented as mean
± SD (n ≥ 3), two-tailed unpaired Student’s t-test: *P-values < 0.05; **P-values < 0.01; ***P-values < 0.001.
due to Cas9 protein upregulation, but this was not the case
for Entinostat. Furthermore, we checked the Cas9 expres-
sion with post-treatment. There were no obvious changes of
Cas9 expression with post-treatment of Panobinostat and
Entinostat (Supplementary Figure S4). These results sug-
gest that Panobinostat may increase Cas9 expression by en-
hancing viral transduction, but not transgene expression.
To investigate the effects of the accessibility of the viral
particles to cell membrane with Entinostat and Panobinos-
tat treatment, we measured the expression levels of cellular
receptor CD46 for adenoviruses by flow cytometry analysis
(32). Our results show that only Panobinostat significantly
increases CD46 expression levels in H27 cells (Supplemen-
tary Figure S6). Thus, Panobinaostat might increase virus
transduction via CD46 upregulation.
DSBs introduced by CRISPR/Cas9 are repaired by ei-
ther non-homologous end joining (NHEJ) or homology di-
rected repair (HDR). However, these two repairing path-
ways favour a specific cell cycle. NHEJ is active through-
out the cell cycle, but it has the highest activity in S and
G2/M stages[17], whereas HDR is most efficient in S and
extremely low in G1 (39). Therefore, HDAC and HAT in-
hibitors might regulate the gene editing efficiency by affect-
ing the cell cycle. Particularly, Panobinostat has been re-
ported to arrest cell cycle at G2/M (40). To determine the
cell cycle changes introduced by Entinostat and Panobi-
nostat, we performed flow cytometry analysis of cell cy-
cle using PI DNA staining incorporating a proliferative
marker BrdU. Panobinostat arrested cells at G2/M (0.075
M and 0.1 M), but we did not observe an obvious cell
cycle change in the treatment of Entinostat (Figure 4D).
Collectively, these results show that Panobinostat and
Entinostat enhance gene knockout by different mecha-
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Figure 4. Alterations of virus transduction, transgene transcription and cell cycle with the treatment of Entinostat and Panobinostat. (A) AdTL-EGFP
transgene expressionwas determined by flow cytometry with the pre- and post-treatment ofHDAC inhibitors. (B) RNA level of Cas9 and gRNA expression
level are measured by qPCR. (C) AdV-Cas9 protein expression was determined by western blot with pre-treatment of HDAC inhibitors (Entinostat 5 M,
Panobinostat 0.1M) andWestern blot quantification. The graph was generated through quantifying blots from three independent experiments by ImageJ.
(D) Cell cycle changes incorporate with Brdu upon HDAC inhibitors treatment with different dose. Data in bar graphs are represented as mean ± SD (n
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cle arrest may contribute to gene knockout enhancement
induced by Panobinostat, which might be different to our
initial hypothesis, whereas, Entinostat is consistent with our
hypothesis.
Entinostat analogues significantly enhance the
CRISPR/Cas9 gene knockout efficiency
Owing to the promising results of Entinostat for im-
proving CRISPR/Cas9 gene editing efficiency, we tested
three analogues of Entinostat to confirm our findings
(31) (Figure 5A). These three Entinostat analogues signif-
icantly increased the gene knockout frequencies (30–52%)
of CRISPR/Cas9 without effects on cell viability (Figure
5B and Supplementary Figure S1B). In consistence with
Entinostat, these analogues have no effect on endogenous
EGFP expression (Figure 5C), Cas9 expression (Figure 5D
and Supplementary Figure S4) and cell cycle (Figure 5E).
Furthermore, we did not observe significant changes of cell
doubling time (41) and morphology with Entinostat treat-
ment, but those changes have been observed with Panobi-
nostat treatment (Supplementary Figure S8).
Panobinostat and Entinostat significantly enhance gene
knock-in (HDR) and knockout (NHEJ)
The gene knock-in efficiency by HDR pathway is much
lower than gene knockout by NHEJ. To investigate whether
our inhibitors can enhance the gene knock-in efficiency, an
EGFP-EBFP converting fluorescent system was employed
(42). This system allows the simultaneous detection of mu-
tagenic NHEJ and HDR events (Figure 6A). In parallel,
the chromatin compaction can be precisely regulated by
Dox (doxycycline) treatment. The heterochromatin will be
formed in the targeted sequences in the absence of Dox. Af-
ter the gene editing process, Dox is added to determine the
frequencies of mutagenic NHEJ and HDR events through
dual-color flow cytometry (Figure 6A).
Entinostat increased themutagenic NHEJ andHDR rate
by ∼2.3-fold, ∼2.4-fold, respectively (Figure 6B). Panobi-
nostat increased the NHEJ and HDR rate by ∼2.6-fold,
∼1.4-fold, respectively (Figure 6B). However, RGFP966 de-
creased both knockout and knock-in. In agreement with the
data from the adenovirus system, alterations of gene knock-
out with this plasmid transient transfection system were
similar, which confirms our previous data. Meanwhile, we
performed a cell viability assay to determine that the con-
centrations of the compounds we used have no effect on cell
proliferation (Supplementary Figure S1C).
We further determined the effects of Panobinostat and
Entinostat on gRNA and Cas9 expression by qRT-PCR
and Western blot. We did not observe changes of Cas9
expression levels after treatment with either Panobinos-
tat or Entinostat (Figure 6C and D). However, the ex-
pression of gRNA increased after treatment of Panobino-
stat (Figure 6C). These results suggest that the enhance-
ment of gene knock-in/knockout by Entinostat is not due
to gRNA and Cas9 expression changes. In addition, we
also checked the Cas9 expression with Panobinostat or
Entinostat post-treatment. Panobinostat slightly enhanced
Cas9 protein level with post-treatment in H27, but this
was not the case for Entinostat (Supplementary Figure S5).
Furthermore, we checked the Cas9 expression with pre-
and post-treatment of all Entinostat analogues (Figure 5A)
and found that there were no increases of Cas9 expres-
sion (Supplementary Figure S5). Additionally, Panobino-
stat and Entinostat showed no significant effect on the cell
cycle of HEK.EGFPTetO.KRAB (Figure 6E).
Chromatin immunoprecipitation (ChIP)-qPCR and MNase
(micrococcal nuclease)-qPCR revealed Entinostat and
Panobinostat introduced an open state of chromatin in the
target loci
To gain insight into the chromatin state at the
CRISPR/Cas9 target region, ChIP-qPCR assays were
performed in the presence or absence of Entinostat (5 M)
and Panobinostat (0.1 M) in H27 cells. A ChIP-grade
antibody against H3Ac (histone3-acetylation), which com-
monly serves as a marker of open chromatin status, was
used. With the treatment of Entinostat and Panobinostat,
the enrichment for the euchromatin marker H3Ac were
∼1.7-fold and ∼2.9-fold higher than with no treatment
group, respectively (Figure 7A). Therefore, the HDAC
inhibitors (Entinostat and Panobinostat) induced the
euchromatin state in the CRISPR/Cas9 target region.
MNase-qPCR is able to precisely determine chromatin
structure and DNA accessibility at specific target loci with
light-digestion conditions by concentration of MNAse (5
U) and the short time of incubation (5 min) (43). There-
fore, we performed MNase-qPCR to measure how Entino-
stat and Panobinostat influenced chromatin structure and
DNA accessibility at CRISPR/Cas9 target region. Our re-
sults show that both Entinostat and Panobinostat can sig-
nificantly increase DNA accessibility around the gRNA
binding site on EGFP (Figure 7B).
To further determine the binding of Cas9 protein and tar-
get loci of chromosome in a direct manner, ChIP-qPCR as-
says were performed using a specific Cas9 antibody as well.
The enrichment of Cas9 protein binding to target DNA
was ∼3.0-fold and ∼1.7-fold higher than the group with no
Entinostat or Panobinostat treatment (Figure 7C). Of note,
enrichment of Cas9 protein binding to targeted DNA was
consistency with gene knock-in results (Figure 6B). Collec-
tively, these results provide direct evidence for HDAC in-
hibitors improving the accessibility of chromatin and in-
creasing the binding of Cas9 and targeted DNA (Figure 8).
Detection of off-target effects by Sanger sequencing
To detect whether Entinostat can increase off-target effects,
we have amplified the DNA by PCR with specific primers
(Supplementary Table S2) and performed Sanger sequenc-
ing to detect four potential off-target sites in genome se-
lected fromCas-OFFinder (36).We did not observe any off-
targets in these regions with/without treatment of Entinos-
tat (5M) (Supplementary Figure S7) in H27 cells. How-
ever, we cannot completely rule out any other remaining
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Figure 5. Entinostat analogues on CRISPR/Cas9 mediated gene editing. (A) The chemical structures of Entinostat and its analogues. (B) Gene knockout
enhanced by Entinostat analogues treatment. (C) Endogenous EGFP expression changes by Entinostat analogues treatment. (D) Cas9 protein expression
changes by Entinostat analogues treatment. (E) Cell cycle changes by Entinostat analogues treatment. The dose of analogues used are 1 M FC-3, 1 M
FC-4, and 10 M FC-11. Data in bar graphs are represented as mean ± SD (n ≥ 3), two-tailed unpaired Student’s t-test: *P-values < 0.05; **P-values <
0.01; ***P-values < 0.001.
DISCUSSION
We comprehensively investigated the impact of HDACs
and HATs on CRISPR/Cas9 mediated gene editing. We
found that Entinostat (HDAC1/2/3 inhibitor) and Panobi-
nostat (pan-HDAC inhibitor) enhanced Cas9 gene edit-
ing activity while other inhibitors (HDAC4/5/6/7/8/9) did
not. We also found that RGFP966 (HDAC3 inhibitor) de-
creased CRISPR/Cas9 gene editing activity, which can be
used for downregulation CRISPR/Cas9 gene editing ac-
tivity. Importantly, Entinostat and Panobinostat dramati-
cally increase gene knock-in rates. We confirmed these find-
ings by knockdown of HDAC1, HDAC2 and HDAC3. We
further identified that HDAC inhibition (Entinostat and
Panobinostat) facilitated Cas9 access to target DNA and
increased cutting frequencies. Our study revealed an es-
sential role of HDACs in CRISPR/Cas9 mediated gene
editing. We demonstrate that it is feasible to modulate
CRISPR/Cas9 gene editing efficiency by regulating HDAC
activity. This method might also be widely used in regulat-
ing other nucleases (ZFNs, TALENs, CRISPR/Cas9 and
dCas9)-mediated genome and epigenome editing.
We showed that inhibition of HDAC1 or HDAC2, but
not other HDACs or HATs, significantly enhances the gene
knockout and knock-in frequencies by uncoiling the chro-
matin structure. Several recent studies showed that the
chromatin structure and nucleosomes dramatically affect
CRISPR/Cas9 mediated gene editing (17,18,20,44). For in-
stance, a study shows that nucleosomes inhibit CRISPR-
Cas9 cleavage activity via blocking binding of Cas9 to
PAM sites (20). Another study shows heterochromatin de-
lays CRISPR-Cas9mutagenesis, but does not affect the out-
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Figure 6. Gene-editing (NHEJ and HDR) based on converting EGFP to EBFP fluorochrome with a plasmids transient transfection system. (A) Schematic
representation of a knockout and knock-in system by converting EGFP to EBFP. (B) Alterations of gene knockout and knock-in with different HDAC
inhibitors treatment. (C) RNA level of Cas9 and gRNA expression level are measured by qPCR. (D) Cas9 protein expression changes with different HDAC
inhibitors treatment using the same dose as shown in knock-in. (E) Cell cycle changes by Panobinostat, Entinostat, and RGFP966 treatment. The dose
of HDAC inhibitors are used as shown. Data in bar graphs are represented as mean ± SD (n ≥ 3), two-tailed unpaired Student’s t-test: *P-values < 0.05;
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Figure 7. Chromatin immunoprecipitation (ChIP) and qPCR analysis of chromatin state and the binding between Cas9 and targeted DNA with HDAC
inhibitors treatment. All CHIP-qPCR andMNAse-qPCR assays were conducted using H27 cell line. (A) ChIP-qPCRwas performed by using the antibody
directly against open chromatinmarksHistone3-acetylation (H3Ac). (B)MNAse-qPCRwas performed by using 5Umicrococcal nuclease. (C) ChIP-qPCR
was performed by using Cas9 antibody directly against the complex of Cas9 protein and the target loci of chromosome. The probed regions were located
closely to CRISPR/Cas9 target sequences (−200 bp, +200 bp). Standard positive and negative controls have been described (18).
Figure 8. A proposed model of HDAC inhibition and CRISPR/Cas9 me-
diated gene editing.HDAC inhibition causes unwinding of the targetDNA
by the addition of acetyl groups to the histones, and thus improving the ac-
cessibility of the DNA for gene editing using the CRISPR/CAS9 system.
This would enable binding of the nuclease to the desired target sequence
and cut the DNA as well as HDR.
tagenesis is mainly depending on Cas9 expression level in-
stead of chromatin state (45). Another study shows that
CRISPR/Cas9 cleavage activity is increased by 2.2-fold by
changing chromatin state with a TetR-KRAB system in the
presence of Dox (18). Thus, different articles have given dif-
ferent answers on how chromatin influences CRISPR/Cas9
targeting from different aspects. Thus, to the best of our
knowledge, the underline mechanisms of how Cas9 inter-
acts with chromatinized DNA are still not clear. There-
fore, we hypothesized that alteration of chromatin state
by HDAC/HAT inhibitors can regulate genome editing by
CRISPR/Cas9. Our data support this hypothesis and fur-
ther show that HDAC1 and HDAC2 play an essential role
in improving CRISPR/Cas9 mediated gene editing. Fur-
thermore, we carried out an in-depth investigation to show
that downregulation of HDAC1 or 2 activities can open the
chromatin and improve the binding between Cas9 proteins
and target DNA.
Our data revealed that HDAC inhibition shows remark-
able enhancements of HDR events. The extremely low gene
knock-in efficiency is one of the main obstacles for gene
editing. Our findings contribute to the understanding gene
editing by HDR in two aspects. Firstly, our study pro-
vides a new practical solution for enhancing gene knock-
in with FDA proved HDAC inhibitors. Furthermore, our
study suggests that histone acetylation and deacetylation
may play an important role in HDR. One possible explana-
tion is that the histone octamer complex around DNAmay
have strong steric effects for large DNA fragment insertion
and integration by HDR. HDAC inhibitors cause unwind-
ing of the targetDNAby the addition of acetyl groups to the
histones, and thus not only improves the accessibility of the
targeted DNA to Cas9 protein, but also to the donor DNA
forHDR. This enables binding of desired target sequence to
the nuclease as well as to donor DNA. Thus, both knockout
and knock-in can be enhanced. In addition, our results also
indicate that the HDR events have a positive correlation to
the binding of Cas9 protein and targeted DNA (Figures 6B
and 7C). Previous study has shown that dissociation ofCas9
protein from double-strandedDNA is∼6 hwhich coincides
with the HDR time ∼7 h (46,47), we speculate that Cas9
protein may have interactions with double-stranded DNA
and facilitate the HDR process during this residence time.
Another study shows that opening chromatin by removing
histones increases rates of HDR (48). Nonetheless, the pre-
cise mechanism of how Cas9 protein interacts with chro-
matinized DNA remains largely unknown. This needs to be
clarified by future studies. Future studies may also need to
clarify howCas9 protein interacts with plainDNA (without
histone) and nucleosomal DNA (with histone).
DSBs repair can also be affected by cell cycle ar-
rest, which will eventually influence the gene editing pro-
cess (49,39). As HDAC inhibitors might affect cell cycle,
we investigated the cell cycle changes with the treatment
of HDAC inhibitors. We found that Panobinostat (pan-
HDAC inhibitor) can increase the proportion of cells in
G2/M phase, but we did not observe any cell cycle changes
with Entinostat. Thus, we have excluded the gene editing
process affected by cell cycle alterations induced by Entino-
stat. In addition, some of the HDAC or HAT inhibitors can
regulate virus transgene expression. Our data has shown
that Panobinostat significantly enhance Cas9 protein ex-
pression. Similarly, pan-HDAC inhibitors, such as Valproic
Acid (VPA), can enhance ZFN expression and cell cycle
modulation (50). Also, another study has shown that pan-
HDAC inhibition (trichostatin A and vorinostat) can be
applied in transient IDLV-mediated ZFN expression mod-
ulation. However, we did not observe significant Cas9 ex-
pression changes in the condition of HDAC1, HDAC2 and
HDAC3 specifically inhibition by Entinostat. Taken to-
gether, multiple factors, including G2/M phase cell cycle
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in Cas9 expression, may contribute to CRISPR/Cas9 gene
editing by Panobinostat. However, our study proved that
gene editing efficiency enhanced by Entinostat is not due to
those factors, but through changing the chromatin state.
Interestingly, inhibition of HDAC3 attenuated
CRISPR/Cas9 gene editing activity, which suggests
that HDAC3 played an extraordinary role in the gene
editing process. It might be possible to use HDAC3 in-
hibitors for turning down the activity of Cas9. The first
small molecular Cas9 inhibitors have been uncovered
recently which can be used for inactivating Cas9 activity
(51). Although those inhibitors are with high potency,
they might be only effective for SpCas9. However, HDAC3
inhibitors can be used for downregulating the gene editing
efficiency through alteration chromatin state regardless
of nucleases. HDAC and HAT inhibitors have shown
mixed results in different studies and in the treatment of
cancers (27). Unlike HDAC1 and HDAC2, which only
function in the cell nucleus, HDAC3 is able to shuttle
between the nucleus and the cytoplasm (52,53). Inhibition
of HDAC3 in the cytoplasm or in the nucleus may have
different effects on Cas9 mediated gene editing process.
Furthermore, HDAC3 is present at DNA replication forks
and inhibition of HDAC3 led to a significant reduction in
DNA replication fork velocity (54). Treatment of HDAC3
inhibitor caused inefficient or slowed DNA replication
(54). This inefficient DNA replication may affect the DSB
repair induced by CRISPR/Cas9 and decrease the gene
editing efficiency. Therefore, this unique feature of HDAC3
may be one of the explanations in the mechanism on the
decreased gene editing efficiency by HDAC3 inhibition.
Off-target effects are a significant concern for
CRISPR/Cas9 technology, especially for clinical use.
Although the aim and scope of our study are to enhance
CRISPR/Cas9 mediated genome editing by HDAC in-
hibition, the risk of off-target effects led by those drugs
is unwanted. We did not observe any off-targets in these
regions with/without treatment of Entinostat. However, we
cannot completely rule out any other remaining off-target
possibilities due to the limitation of our detection methods.
It will be of great interests to further deeply investigate
whether HDAC inhibitors might increase off-target effects
for future study.
In conclusion, our study provides a practical option for
improving gene editing efficiency through chromatin de-
condensation using HDAC inhibition. Furthermore, our
study facilitates a deeper understanding of gene editing pro-
cess by altering the accessibility of the DNA through his-
tone acetylation and histone deacetylation.
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